Overview

Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)

Status:
RECRUITING
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
EMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFN, may improve the outcome of patients with sepsis driven by the IDS (endotype of IFN-driven sepsis) endotype. EMBRACE also aims to identify the best dosing regimen of emapalumab for the management of IDS.
Phase:
PHASE2
Details
Lead Sponsor:
Hellenic Institute for the Study of Sepsis